Amazon Web Services (AWS) has introduced Amazon Bio Discovery, a new application that integrates computational design and wet-lab validation into a single platform. The system provides access to more than 40 AI biology models and allows users to upload custom or third-party models. It includes agentic assistants that guide researchers in model selection, configuration, and candidate evaluation. The platform connects directly with contract research organization partners for seamless lab testing, with results automatically feeding back to improve subsequent research cycles.
According to AWS, the tool aims to remove collaboration bottlenecks between computational biologists and bench scientists by offering a no-code environment for workflow creation and experiment management. Computational experts can build reusable workflows with standardized data processing, while bench scientists can run parallel experiments and adjust parameters without coding. Both groups work from the same data and results, improving reproducibility and speed.
Amazon Bio Discovery is built on AWS infrastructure used by major pharmaceutical companies and is available immediately with enterprise-grade security. The platform is designed to make lab-in-the-loop drug discovery scalable and accessible across research organizations.
Lab-in-the-loop drug discovery has transformed research for some organizations. AI-powered predictions improve continuously through wet-lab feedback, accelerating the path from hypothesis to validated candidates. But for most research teams, the real
The ‘1 Nojor’ media platform is now live in beta, inviting users to explore and provide feedback as we continue to refine the experience.
